Evidence map›Paper›PMID 31094423›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020

Early Signals of Vaccine-driven Perturbation Seen in Pneumococcal Carriage Population Genomic Data.

Chrispin Chaguza, Ellen Heinsbroek, Rebecca A Gladstone, Terence Tafatatha, Maaike Alaerts, Chikondi Peno, Jennifer E Cornick, Patrick Musicha, Naor Bar-Zeev, Arox Kamng'ona and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Genomic epidemiology ofFrontiers in cellular and infection microbiology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Genomic surveillance of invasiveMicrobial genomics · 2021
    Article
  9. Microbial genomics · 2021
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 5 countries.

Chrispin ChaguzaParasites and Microbes Programme, Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge.
Ellen HeinsbroekDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, United Kingdom.
Rebecca A GladstoneParasites and Microbes Programme, Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge.
Terence TafatathaMalawi Epidemiology Intervention Research Unit (formerly KPS), Chilumba.
Maaike AlaertsMalawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre.
Chikondi PenoMalawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre.
Jennifer E CornickDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, United Kingdom.
Patrick MusichaDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, United Kingdom.
Naor Bar-ZeevDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, United Kingdom.
Arox Kamng'onaDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, United Kingdom.
Aras KadiogluDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, United Kingdom.
Lesley McGeeRespiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.
William P HanageCenter for Communicable Disease Dynamics, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Robert F BreimanHubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Robert S HeydermanMalawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre.
Neil FrenchDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, United Kingdom.
Dean B EverettMalawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre.
Stephen D BentleyParasites and Microbes Programme, Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge.
University of Liverpool · GBCenter for Disease Dynamics, Economics & Policy · USCenters for Disease Control and Prevention · USEmory University · USJohns Hopkins University · USMalawi Epidemiology and Intervention Research Unit · MWWellcome Sanger Institute · GB

Funding

Ecological and genetic contributions to the spread of resistance in pneumococcusR01AI106786 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HANAGE, WILLIAM · 2013 to 2017
$3.1M
Medical Research Council MR/P011284/1Medical Research Council MR/R002592/1Medical Research Council MR/R003076/1NIAID NIH HHS R01 AI106786Wellcome TrustWellcome Trust 084679/Z/08/Z
6 · The paper itself

Abstract

backgroundPneumococcal conjugate vaccines (PCVs) have reduced pneumococcal diseases globally. Pneumococcal genomic surveys elucidate PCV effects on population structure but are rarely conducted in low-income settings despite the high disease burden.

methodsWe undertook whole-genome sequencing (WGS) of 660 pneumococcal isolates collected through surveys from healthy carriers 2 years from 13-valent PCV (PCV13) introduction and 1 year after rollout in northern Malawi. We investigated changes in population structure, within-lineage serotype dynamics, serotype diversity, and frequency of antibiotic resistance (ABR) and accessory genes.

resultsIn children <5 years of age, frequency and diversity of vaccine serotypes (VTs) decreased significantly post-PCV, but no significant changes occurred in persons ≥5 years of age. Clearance of VT serotypes was consistent across different genetic backgrounds (lineages). There was an increase of nonvaccine serotypes (NVTs)-namely 7C, 15B/C, and 23A-in children <5 years of age, but 28F increased in both age groups. While carriage rates have been recently shown to remain stable post-PCV due to replacement serotypes, there was no change in diversity of NVTs. Additionally, frequency of intermediate-penicillin-resistant lineages decreased post-PCV. Although frequency of ABR genes remained stable, other accessory genes, especially those associated with mobile genetic element and bacteriocins, showed changes in frequency post-PCV.

conclusionsWe demonstrate evidence of significant population restructuring post-PCV driven by decreasing frequency of vaccine serotypes and increasing frequency of few NVTs mainly in children under 5. Continued surveillance with WGS remains crucial to fully understand dynamics of the residual VTs and replacement NVT serotypes post-PCV.

Indexed as

MetagenomicsPneumococcal InfectionsCarrier StateChildHumansInfantMalawiNasopharynxPneumococcal VaccinesSerogroupStreptococcus pneumoniaeVaccines, ConjugatePneumococcal VaccinesVaccines, Conjugatecarriagegenomicspneumococcusserotypes

Identifiers

PMID31094423
PMCPMC7768739
OpenAlexW2950220193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.